Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: mistake (35), fault (22), slip (31)

Sunitinib v1.1

Description: Regimen Renal Cell - Sunitinib Indication Chemotherapy Protocol RENAL CELL SUNITINIB First line treatment of advanced or metastatic renal cell carcinoma WHO
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Sunitinib-v1.1.pdf

Pazopanib v1.1

Description: Chemotherapy Protocol RENAL CELL PAZOPANIB Regimen Renal Cell - Pazopanib Indication First line treatment option for people with advanced renal cell carcinoma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Pazopanib-v1.1.pdf

Rituximab SC (8 weekly) Ver 1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (8 weekly) Regimen Lymphoma – Rituximab SC (8 weekly) Indication Maintenance single agent therapy in previously untreated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-8-weekly-Ver-1.pdf

Rituximab SC (12 weekly) Ver1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (12 weekly) Regimen Lymphoma – Rituximab SC (12 weekly) Indication Maintenance single agent therapy in relapsed / refractory
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-12-weekly-Ver1.pdf

Rituximab (8 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (8 Weekly) Regimen Lymphoma – Rituximab (8 weekly) Indication Non-Hodgkin’s Lymphoma as first-line maintenance therapy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-8-weekly.pdf

Rituximab (12 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (12 weekly) Regimen Lymphoma – Rituximab (12 Weekly) Indication Non- Hodgkin’s Lymphoma as maintenance monotherapy for relapsed
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-12-weekly.pdf

Lenalidomide Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA LENALIDOMIDE There are multiple versions of this protocol in use. Please ensure you have the correct protocol for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-Ver-1.1.pdf

Ibrutinib (MCL) (560mg)

Description: Chemotherapy Protocol Mantle Cell Lymphoma Regimen Ibrutinib • MCL – Ibrutinib (560mg) Indication • Mantle Cell Lymphoma with cyclin D1 overexpression or translocation breakpoints
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Ibrutinib-MCL-560mg.pdf

FC PO (5 day)-Cyclophosphamide-Fludarabine PO 5 day Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-FLUDARABINE ORAL 5 DAY (FC PO 5 day) Regimen Lymphoma – FC PO (5 day)-Cyclophosphamide-Fludarabine PO
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/FC-PO-5-day-Cyclophosphamide-Fludarabine-PO-5-day-Ver-1.1.pdf

Cyclophosphamide-Etoposide PO Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-ETOPOSIDE ORAL Regimen Lymphoma – Cyclophosphamide-Etoposide PO Indication Palliative treatment of malignant lymphoma Toxicity Drug Adverse Effect
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Etoposide-PO-Ver-1.1.pdf

161 to 170 of 630

Previous … 15 16 17 18 19 … Next